Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
about
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerCost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.Cost-utility analyses of drug therapies in breast cancer: a systematic review.The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)The Quality of Quality-of-Life and Cost-Effectiveness AnalysesHealth-state utility values in breast cancer.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.Cost-utility analysis of adjuvant therapies for breast cancer in Iran.Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.Economic evaluation of docetaxel for breast cancer
P2860
Q26748855-E6AB7796-1B8A-47DF-9590-F00F68E6CF8AQ31046050-2FAA3E54-6DE3-4E21-A5D3-C1F30CEF5016Q33680393-444457E1-5DFA-45C3-9A77-87CEED670E76Q34431985-27A0B018-F828-4A04-B3FB-76FE8D5562BDQ34761601-D5D4A70A-AB0A-42DE-9A40-ED2C9714713CQ35573019-5D315A1F-C113-4DD4-91B6-6E894914AAB6Q36116276-09468360-68FF-4DF8-9E65-FA4178D883D4Q36364504-3BAB5C0C-D494-4C07-A322-FD50A273CE3CQ37072523-13793D87-7013-4F86-A267-04408601D655Q37800481-64FD62C6-9715-4C2B-A9DF-E547A92F5E98Q38152967-A888C957-38B9-4845-85E6-3EC22C0FABE2Q39305209-19E33402-31E6-4AAC-9FC2-173432B9B4EAQ44401570-57D32F5F-A27E-4AD0-B1EE-D4221D9E6382Q45802851-2ECE71F7-E265-4BA9-AAE5-A8000ED18F53Q46004078-E9F4EBDF-1A5E-4815-B274-31C021D2D6A4Q51732668-287E7F56-DE00-4C64-B02F-F3D2F665102FQ57142650-678688AC-A288-47DF-ADAA-D7D395265567
P2860
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Docetaxel in combination with ...... ess and cost-utility analysis.
@en
Docetaxel in combination with ...... ess and cost-utility analysis.
@nl
type
label
Docetaxel in combination with ...... ess and cost-utility analysis.
@en
Docetaxel in combination with ...... ess and cost-utility analysis.
@nl
prefLabel
Docetaxel in combination with ...... ess and cost-utility analysis.
@en
Docetaxel in combination with ...... ess and cost-utility analysis.
@nl
P2093
P356
P1476
Docetaxel in combination with ...... ess and cost-utility analysis.
@en
P2093
Adrian Bagust
David A Cameron
Helen C Tate
Sorrel E Wolowacz
P304
P356
10.1200/JCO.2006.10.4190
P407
P577
2008-02-01T00:00:00Z